Metastatic Breast Cancer 2025 UPDATE
Two Onc Docs
00:00
Later-Line Targeted Options and Niche Biomarkers in TNBC
Kareen advises checking for rare targets (NTRK, RET) and considering targeted agents like larotrectinib, entrectinib, selpercatinib, plus clinical trials.
Play episode from 09:59
Transcript
